کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5970919 | 1576179 | 2014 | 7 صفحه PDF | دانلود رایگان |
- In real world adherence to guidelines for management of atrial fibrillation is poor.
- Adherence to guidelines improves survival up to three years.
- Use of oral anticoagulants improves survival.
- The rate control was the prevailing used strategy.
- Survival during the first year was higher with rate control strategy.
ObjectiveDetermining the adherence to ACC/AHA/ESC 2006 guidelines and its influence on the survival of patients with atrial fibrillation.MethodsProspective observational study of patients discharged during 2007 from an Internal Medicine department with a main or secondary diagnose of atrial fibrillation. The stroke risk was estimated with the CHADS2 score. The follow-up was carried out in outpatient medical office or via telephone.ResultsWe included 259 patients (mean age 80.9 years); 73% of them had a high risk of stroke. Oral anticoagulants were administered to 134 (51.7%), and antiplatelet drugs to 71 (27%) patients. A rate control strategy was chosen for 155 (59.8%) patients and a rhythm control one for 28 (10.8%). In 100 (38.6%) patients, treatment was adherent to the guidelines. Adherence to the guidelines was associated with age (0.95 95%CI 0.92-0.99; p = 0.03), contraindication to the use of oral anticoagulants (0.38 95%CI 0.18-0.81; p = 0.01) and mitral valve heart disease/valvular prosthesis (2.10 95%CI 1.04-4.25; p = 0.04). The median follow-up was 727 days, and 191 patients died. Patients treated according to the guidelines had a higher rate of survival during the first three years (0.47 vs. 0.36; p = 0.049). The use of oral anticoagulants was associated with a higher probability of survival over a 5 year period (0.34 vs 0.21; p = 0.001) and the rate control strategy during the first year (0.69 vs 0.57; p = 0.04).ConclusionsIn the real world, the treatment of atrial fibrillation according to the guidelines is associated with improved survival for up to three years during follow-up.
Journal: International Journal of Cardiology - Volume 176, Issue 2, 20 September 2014, Pages 430-436